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A B S T R A C T
The prevalence of the fragile X premutation (55–200 CGG repeats) among the general population is relatively
high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical
outcomes.
In this study we investigated the correlations between molecular measures (CGG repeat size, FMR1 mRNA,
FMRP expression levels, and methylation status at the promoter region and in FREE2 site) and clinical
phenotypes (anxiety, obsessive compulsive symptoms, depression and executive function deficits) in 36 adult
premutation female carriers and compared to 24 normal control subjects.
Premutation carriers reported higher levels of obsessive compulsive symptoms, depression, and anxiety, but
demonstrated no significant deficits in global cognitive functions or executive function compared to the control
group. Increased age in carriers was significantly associated with increased anxiety levels.
As expected, FMR1 mRNA expression was significantly correlated with CGG repeat number. However, no
significant correlations were observed between molecular (including epigenetic) measures and clinical
phenotypes in this sample. Our study, albeit limited by the sample size, establishes the complexity of the
mechanisms that link the FMR1 locus to the clinical phenotypes commonly observed in female carriers
suggesting that other factors, including environment or additional genetic changes, may have an impact on the
clinical phenotypes. However, it continues to emphasize the need for assessment and treatment of psychiatric
problems in female premutation carriers.
1. Introduction
Fragile X mental retardation 1 (FMR1) premutation alleles are
characterized by an expansion of 55–200 CGG repeats and high levels
of FMR1 mRNA [55]. In the United States, about 1 in 260–420 males
and 1 in 151–209 women carry a premutation allele [48,57].
Premutation carriers are at risk of developing endocrine and
neurological problems, particularly fragile X–associated premature
ovarian insufficiency (FXPOI). Approximately 20% of female premuta-
tion carriers, particularly those carrying a premutation allele in the
80–100 CGG repeat range, suffer from altered ovarian function
[27,39,51], compared to about 1% of women without the premutation
in the general population [3,16,54]. In addition, premutation carriers
are at risk for the late onset neurodegenerative disorder fragile X-
associated tremor/ataxia syndrome, FXTAS [28]. FXTAS is character-
ized by ataxia, intention tremor, dementia, mood disorders, and global
executive function deficit (reviewed in [26]). About 40–50% of males
carrying a premutation allele develop FXTAS while only 8 to 16% of
female carriers above 50 years old, were found to develop FXTAS
[4,7,35].
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Premutation carriers can present with a variety of phenotypic
characteristics including executive function deficits [13], social diffi-
culties [18], psychological vulnerability [5], increased risk for autism
spectrum disorder [5,11,17,22], hypertension, sleep apnea, migraine,
and immune-mediated disorders (reviewed in [27]). Increased age,
together with FMR1 mRNA gain of function toxicity may be synergistic
in contributing to severity of neurodegenerative symptoms [28,55,34].
Several studies have shown an age-related deterioration in motor,
cognitive, and anxiety symptoms in female carriers [1,42,52]. Accord-
ing to Yang et al. [61,62], female carriers have impairments in frontal
lobe-mediated tasks such as working memory, performance monitoring
executive functions, and processing speed. Furthermore, evidence
suggests that both anxiety and depression are characterized by execu-
tive dysfunction in young women [63,64]. Interestingly, female pre-
mutation carriers demonstrated significantly higher scores of self-
reported anxiety and depression compared to control subjects that
were correlated with executive functions including working memory
and inhibitory control [37]. These findings suggest that neuropsycho-
logical tests on executive functions might be useful in identifying
markers of risk for psychiatric problems in female premutation carriers
[37]. Recent studies have suggested that female carriers exhibit mild
deficits in executive function [37,53], mathematical reasoning [38,49],
working memory [62] and visuospatial processing [23]. They also
experience a higher rate than expected in the general population of
psychiatric disorders predominantly depression, anxiety, and obsessive
compulsive symptoms [9,43,45,47,50].
Most prior studies examining correlation between psychiatric
symptoms or cognitive profiles and molecular measures in premutation
female carriers were based on CGG allele size, FMR1 mRNA expression
levels and the FMR1 activation ratio (AR; indicating the percent of cells
carrying the normal allele on the active X chromosome) [39]. Among
these molecular measures, the correlations between CGG repeat size
and psychiatric symptoms seem to be the most controversial. There
have been reports of no significant associations [18,29,38], reports of
inverse correlation where women with< 100 repeats have higher risk
while those with> 100 repeats have lower risk for depression and/or
anxiety [39,43], and positive correlations in which longer repeats have
higher risk of comorbidity with symptoms [36,47]. Despite the
extensive correlation studies of clinical phenotypes with FMR1 pre-
mutation carriers, there is no definite biomarker to identify risk and
characteristics of molecular mechanisms contributing to these clinical
phenotypes. Several studies showed a curvilinear association between
the size of FMR1 CGG repeat and a group of symptoms in premutation
carriers, such as major depressive disorder [39,43,44], anxiety and
depressive symptoms in response to stress from negative life events [48]
and menopausal age [16,40]. This finding indicates that the effect of
FMR1molecular measures on the phenotype is quite complex and needs
further investigation.
Recently, a novel epigenetic marker, the fragile X–related epigenetic
elements 2 (FREE2), was identified and found to be hypermethylated in
FXS individuals and unmethylated in controls and in the majority of
premutation carriers [19]. Further studies suggested that FREE2
methylation levels can predict executive functions and/or psychiatric
disorders in premutation female carriers. Specifically the methylation
of several CG sites (CpG) within FREE2 (CpG 6/7 and 10–12)
significantly correlated with dysexecutive functions and/or depression
and anxiety [14]. It was suggested that FMR1 intron 1 methylation
threshold in addition to the activation ratio (AR) could be used to
classify premutation female carriers into two categories: lower and
greater risk for psychiatric and dysexecutive pattern of symptoms.
In this study, we investigated if altered molecular phenotypes in the
FMR1 gene, such as methylation status, CGG repeats number, FMR1
mRNA and FMRP expression levels could account for the clinical
phenotypes that are observed in premutation female carriers including
executive functions (working memory, response control, and attention)
and psychiatric problems, including obsessive compulsive symptoms,
anxiety, and depression.
2. Materials and methods
2.1. Subjects
Individuals were recruited through the MIND Institute Fragile X
Research and Treatment Center, by postings in the community, through
the National Fragile X Foundation or by being participants in research
studies involving premutation carriers carried out at the MIND
Institute. Participants provided informed consent according to proto-
cols approved by the UC Davis Institutional Review Board.
Participants included 24 healthy females (mean age = 30,
SD = 7.5) and 36 premutation female carriers (mean age = 37.5,
SD = 12.8). This study is an expansion to our previously reported
analysis [24], which examined acute and chronic mental health
problems in 24 of the 36 premutation carriers in the current study
(mean age = 30.5, SD = 8.03).
In the current study, 46.7% of the participants were married, 43.3%
were never married and 10% were divorced. The overall sample
included the following races/ethnicities: Caucasian-White (73.3%),
Hispanic (16.6%), Asian (3.3%), not Hispanic/more than one race
(3.3%), and African American (1.6%). Education level was 3.3% high
school diploma, 13.3% had some college studies and 83.4% had
bachelor's degree or higher.
3. Molecular measures
3.1. CGG sizing by PCR and Southern blot analysis
Genomic DNA was isolated from peripheral blood using standard
procedures (Qiagen, Valencia, CA) as previously described [58]. CGG
sizing and methylation status were performed using a combination of
Southern blot and PCR analysis. Fully validated methylation-sensitive
Southern blot, including appropriate controls, was performed on
isolated genomic DNA digested with EcoRI/NruI, transferred on a
nylon membrane and hybridized with the FMR1 specified, dig-labeled,
StB12.3 probe. Details of the method are as previously described [58].
CGG sizing was also assessed by AmplideX® PCR assay, a sensitive and
efficient amplification approach as described elsewhere [10]. PCR
products were visualized by capillary electrophoresis (ABI 3130 XL
Genetic Analyzer, Applied Biosystems) following manufacturer instruc-
tions. Analysis of fragment-sizing data for size analysis was performed
using Peak scanner software (Applied Biosystems).
3.2. Methylation status
Activation ratio was measured based on the intensity of the
appropriate bands on Southern blots as reported in [58]. FREE2
methylation analysis was performed by bisulfite treatment and Sanger
sequencing. DNA samples were treated with bisulfite using the EZ DNA
Methylation-Gold Kit (Zymo Research; Irvine, CA) as per manufac-
turer's instructions. Initial PCR conditions were determined and opti-
mized to amplify the coding region of FREE2 for unconverted samples.
100 ng genomic DNA was used as the template. Reactions contained
0.5 μl each of 10 μM forward (5′-CTG AAG AGA AGA TGG AGG AGC
TGG-3′) and reverse (5′-AGA GGG GCT TCC AAC AGG CCC C-3′)
amplification primers (Integrated DNA Technologies; Coralville, IA).
Cycling conditions were as follows: 95 °C for 2 min, 35 cycles of 95 °C
for 1 min, 60 °C for 1 min, 72 °C for 1 min, followed by 72 °C for
10 min, and a final 4 °C hold. Each bisulfite-converted sample was
analyzed in a second PCR reaction, carried out using 50 ng of converted
template, 2.5 μl 10× buffer with 15 mM MgCl2, 2.5 μl of 10 mM
dNTPs, and 0.4 μl of 5 U Taq DNA Polymerase (Invitrogen Corporation;
Carlsbad, CA). Amplification was conducted using 10 μM forward (5′-
TTG AAG AGA AGA TGG AGG AGT TGG-3′; Eurofins Genomics;
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Louisville, KY) and reverse (5′-TCC AAA CCT TCC CTC CCA ACA ACA-
3′; Integrated DNA Technologies; Coralville, IA) primers. The reaction
mix was pre-activated for 15 min at 95 °C, followed by 45 cycles of
94 °C for 20 s, 61 °C for 30 s, 72 °C for 1 min, followed by 72 °C for
3 min and a final 4 °C hold. Confirmation of the correctly-sized band
was determined by agarose gel electrophoresis (2%, 130 V, 30 min).
A standard protocol to chemically transform One Shot® TOP10
competent E. coli was undertaken using 2 μl of the final TOPO® TA
Cloning reaction containing the PCR product (Thermo Fisher Scientific,
Inc.; Waltham, MA). For control and premutation female samples, 25
single colonies were confirmed to contain the FREE2 region-of-interest
by colony PCR analysis. Complete ligation and successful transforma-
tion were confirmed by agarose gel electrophoresis (2%, 130 V, 30 min)
and correctly-sized amplicons were selected for sequencing analysis.
A control experiment, randomly testing eight samples, included four
control subjects and four premutation carriers (the latter with activa-
tion ratios of 0.1, 0.7, 0.51, and 0.52 respectively). Samples were
analyzed by bisulfite treatment analysis to check for concordance
between activation ratio, as ascertained by methylation at the NruI
site by Southern blot analysis, and the percent methylation as measured
by bisulfite treatment at the NruI site. The forward and reverse primers
within the promoter region for converted samples were: 1F7A (5′-AAT
TTT AGA GAG GTY GAA TTG GGA TAA-3′), F3A (5′-CCC TCT CTC TTC
AAA TAA CCT AAA A-3′), and 1F6A (5′-ACC CTC CAC CYA AAA TAA
AAC-3′) (Eurofins Genomics; Louisville, KY). Cycling conditions were as
follows: 95 °C for 2 min, 35 cycles of 95 °C for 30 s, 55 °C for 30 s, 72 °C
for 1 min, followed by 72 °C for 5 min.
3.3. RNA isolation and FMR1 mRNA expression levels
Total RNA was isolated prepared from 3 ml of blood collected in
Tempus tubes (Applied Biosystems, Foster City, California, USA) or
from 1 × 106 cells using Trizol (Life Technologies, Carlsbad, California,
USA). The measurement of FMR1 mRNA expression levels was carried
out by quantitative Real Time RT-PCR on totRNA using custom
designed Taqman gene expression assays (Applied Biosystems) as
previously described [55,56].
3.4. FMRP expression levels
We used Cisbio Human FMRP assay (63ADK038PEC0 for detection
of fragile X mental retardation protein (FMRP)). The assay used HTRF
technology. It involves a sandwich format with two specific monoclonal
antibodies conjugated to fluorescent dyes. The donor labeled with
Eu2+-Cryptate and donor d2. Lymphocyte and fibroblast samples were
lysed with lysis buffer for 3 h, using Roche Complete Ultra Protease
Inhibitor Tablets (05 892 988 001). Total protein concentration
performed by Thermo Fisher MicroBCA Assay (23235). 6 μg/RXN and
3 μg/RXN total protein was used in triplicates in a 384-well format
following the instructions on assay protocol. Samples were incubated
overnight with both antibodies and read on the PerkinElmer VictorX5.
3.5. Cognitive and psychological measures
The executive function assessments included the working memory
index from Wechsler Adult Intelligence Scale, 3rd Edition (WAIS-III)
[60], and the Response Control Quotient and Attention Quotient from
the Integrated Visual and Auditory Continuous Performance Test (IVA)
[46]. Self-reported psychological symptoms, notably the obsessive
compulsive symptoms T-Score, Anxiety T-score and Depression T-Score
were used from the Symptom Checklist 90 revised (SCL-90-R) [15].
Lifetime presence of anxiety disorder was identified by the clinician-
administered Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I) [41].
3.6. Statistical analysis
Subject age was compared between groups using a two sample t-
test, and distributions of categorical subject demographic characteris-
tics were compared between groups using Fisher's Exact Test. The
association of subject age and of activation ratio with continuous
clinical measures was analyzed using linear regression and the associa-
tion of subject age and activation ratio with ordinal clinical measures
was analyzed using proportional odds logistic regression. Continuous
clinical measures were compared between groups using linear models,
and ordinal clinical measures were compared between groups using
proportional odds logistic regression models, with age included as a
covariate in both cases. Likewise, the associations between clinical data
and FMR1, FMRP and CGG repeat length were analyzed using linear
models in the case of continuous clinical measures and proportional
odds logistic regression in the case of ordinal clinical measures; all
models allowed for separate effects in control and premutation subjects
and included age as a covariate. Linear regression was used to test for
associations between molecular measures. P-values were adjusted for
multiple testing within each table using the Benjamini-Yekutieli false
discovery rate controlling method [6]. Analyses were conducted using
R, version 3.3.1 [59].
Post-hoc power calculations are not included, as these contribute no
additional information beyond that provided by the confidence inter-
vals and P-values already shown, as detailed in [32].
4. Results
4.1. Demographics and clinical features
The mean age of premutation subjects was significantly greater than
that of control subjects (t = 2.83, 57.3 df, P = 0.006). The mean
number of CGG repeats was 32 in the control group compared to 86
in premutation carriers (Table 1). Among the female premutation
carriers, five were mothers of children with FXS, two had children
with a premutation and one had a typical child. In addition, 11.1% had
a history of FXPOI and none had FXTAS. We found that among the
female premutation carriers, 50% had significantly elevated current
depression, 33.3% anxiety and 61.1% obsessive compulsive symptoms
compared to 8.3%, 4.2% and 12.5% respectively, in the control group
(Fig. 1, Table 2; adjusted P = 0.017 for depression, P = 0.049 for
anxiety and P = 0.019 for obsessive compulsive symptoms).
When using SCL-90R, the linear models and proportional odds
logistic regression models comparing clinical measures between groups
showed that mean scores for anxiety (adjusted P = 0.049), obsessive
compulsive symptoms (adjusted P = 0.019), and depression (adjusted
P = 0.017), were all significantly higher in the premutation group than
in the control group after adjusting for age. When observing the effect
of age on lifetime history of DSM-IV disorders, increased age was
associated with greater likelihood of anxiety disorder (adjusted
P = 0.008). None of the other clinical measures (SCID-Depression
and SCID-obsessive compulsive symptoms) was significantly correlated
with subject age after adjustment for multiple testing (Table 2). On the
other hand, when comparing groups on lifetime history of DSM-IV
disorders, there was no association of any of the SCID measures with
premutation carriers compared to female controls although a margin-
ally significant increased rate of lifetime anxiety disorder was observed.
4.2. Correlation among molecular measures
Results from linear regression models for pairs of molecular
measures showed that, as expected, FMR1 mRNA expression was
significantly correlated with CGG repeat number (adjusted
P = 0.001). No significant correlations were observed among the other
molecular measures.
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4.3. Correlation between clinical outcomes and molecular measures
No clinical measures were found to be associated with FMRP, CGG
repeat number, FMR1 mRNA levels, FMRP levels, activation ratio or
FREE2 methylation sites following correction for multiple testing and
adjusting for age (Figs. 2 and 3).
5. Discussion
This study examined correlations between molecular measures at
the FMR1 locus and key clinical outcomes in female premutation
carriers. Our findings show that the premutation group had signifi-
cantly higher current symptoms than control group for obsessive
compulsive symptoms, depression, and anxiety, and a marginally
significant increased rate of lifetime anxiety disorder after multiple
comparison and age adjustment.
These results are consistent with previous studies that premutation
females tend to report more psychological difficulties compared to
control groups [29,39,47,55,56]. Notably, in our premutation group
11% (4 out of 36 subjects) were affected by FXPOI, 13.8% (5 out of 36
subjects) have children by FXS, 5.5% (2 out of 36 subjects) and had
children with a premutation. Therefore, it is unlikely that these
psychiatric symptoms may be caused by distress of raising children
affected by FXS, observations consistent with previous reports
[24,43,44]. Roberts et al. [43] reported that nearly half of the
premutation participants (48%) in their study had depression before
having affected children with FXS. Another study by the same group
[44] revealed that the rates of depression and anxiety disorders did not
differ between females over age 40 with and without FXPOI despite the
high prevalence of FXPOI in this cohort (41%). Therefore, the presence
of absence of FXPOI or children with FXS was not proven to be of
significant influence on the psychological symptoms in female pre-
mutation carriers.
Our previous study showed that premutation carriers were at a
significantly higher risk of having psychiatric problems such as anxiety,
depression and OC symptoms compared to normal females [24].
Interestingly, we found a significant positive correlation between age
and anxiety confirming a finding that has been previously reported in
this population.
Previous studies demonstrated that premutation carriers were prone
to meet criteria for major depression, panic disorder, and specific
phobias at a later onset compared to a control group. The late onset
might be influenced by biological and psychosocial factors. This comes
in line with the findings in our study in which 53.3% of female carriers
with a mean age of 37.5 years were shown to have clinically significant
anxiety symptoms compared to 8.3% of the control group. Furthermore,
approximately 66.6% of premutation group had clinically elevated
depressive symptoms and 23.3% reported OC symptoms. The FMR1
mRNA toxicity derived from the observed elevated FMR1 mRNA
expression levels, may perturb certain cortical areas as well as the
limbic system [30]. This in turn may contribute to brain changes [1]
and a higher risk of having neurodegenerative disorders and difficulties
dealing with multiple distresses throughout their lives [50]. However,
in this study we did not observed a correlation between FMR1 mRNA
expression levels and psychiatric problems, due perhaps to the small
sample size, potentially to the weaker effect observed in females [29] or
to the difference in mRNA expression levels between peripheral blood
and different areas of the brain. Thus, this hypothesis awaits further
longitudinal study.
Working memory and attention did not differ between the premuta-
tion and the control groups. These findings suggest that the premuta-
tion carriers in our study have intact cognitive abilities, despite
experiencing higher levels of depression, obsessive compulsive symp-
toms and anxiety. The results obtained from the selected executive
functions assessments (Working memory index, response quotient, and
attention) indicate that the premutation carriers in this study have
similar global cognitive functions to that of the control group. This was
also reported to be the case in previous studies of both adult male
premutation carriers [2,25,31] and of a larger female sample size
[33,39].
Similar to our results, two previously published studies showed no
differences in neuropsychological abilities among premutation carriers
without FXTAS and non-carriers [2,33]. Allen et al. [2] investigated the
effect of CGG repeat numbers on cognitive performance of 84 female
premutation carriers compared with 74 control subjects using the
Wechsler Adult Intelligence Scales-Third Edition (WAIS-III) and found
no significant differences. However, the premutation group showed
marginally decreased Verbal IQ. Hunter and colleagues [33] further
expanded the study to cover 293 women with premutation alleles and
117 normal participants examining six factors of neuropsychological
function including visual processing and memory, verbal comprehen-
Table 1
Subject characteristics by group.
Control
(n = 24)
Premutation
(n = 36)
All subjects
(n = 60)
P-value
CGG repeats n/a
N 24 36 60
Mean (SD) 31.8 (4.1) 86.1 (19.6) 64.4 (30.9)
Median (range) 30 (28–47) 85 (56–152) 69 (28–152)
Molecular category
(n, %)
n/a
0 24 (100%) 0 24 (40%)
2 0 36 (100%) 36 (60%)
Age 0.006
N 24 36 60
Mean (SD) 30 (7.5) 37.5 (12.8) 34.5 (11.5)
Median (range) 27.5
(20–47)
35 (19–76) 32.5 (19–76)
Race (n, %) 0.275
African American 0 1 (2.8%) 1 (1.7%)
Asian 2 (8.3%) 0 2 (3.3%)
Hispanic 3 (12.5%) 2 (5.6%) 5 (8.3%)
More than one race 2 (8.3%) 2 (5.6%) 4 (6.7%)
White 17 (70.8%) 31 (86.1%) 48 (80%)
Marital status 0.801
Divorced 3 (12.5%) 3 (8.3%) 6 (10%)
Married 10 (41.7%) 18 (50%) 28 (46.7%)
Never married 11 (45.8%) 15 (41.7%) 26 (43.3%)
Education level (n,
%)
0.064
HS diploma/GED 0 2 (5.6%) 2 (3.3%)
Associates degree 1 (4.2%) 1 (2.8%) 2 (3.3%)
Some college
studies
7 (29.2%) 1 (2.8%) 8 (13.3%)
Bachelors 9 (37.5%) 17 (47.2%) 26 (43.3%)
Some grad/
professional
school
3 (12.5%) 6 (16.7%) 9 (15%)
Graduate/
professional
degree
4 (16.7%) 9 (25%) 13 (21.7%)
Fig. 1. Bar chart showing comparison of clinical phenotypes between the control and
premutation groups using SCL-90R.
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sion and memory, processing speed, self-report of inattention and
impulsivity, sustained attention, and response fluency. They found no
significant correlation between these clinical measures and CGG repeat
length within the female premutation group. However, they reported a
moderate and significant increase in self-reported inattention and
impulsivity in premutation carriers relative to controls respectively.
They suggested that females with the premutation might be at higher
risk of having some symptoms of ADHD.
As expected, we found that CGG repeat number, adjusted for the AR,
was significantly correlated with FMR1 mRNA expression. CGG repeat
size was also significantly correlated with FMRP but this significance
was lost after multiple comparison adjustment. On the other hand,
linear regression models showed no correlations between clinical and
molecular measures including CGG repeat numbers, FMR1 mRNA,
FMRP, activation ratio, and FREE2 methylation in premutation carriers
compared to the control group. These findings are consistent with
previous studies [8,12,18,20,21,24,29,38].
In our previous report [24], no correlation was shown between CGG
repeat size or FMR1 mRNA with scores of psychiatric symptoms as
measured by SCL-90R in the premutation group. In this study, we
further investigated the potential correlations of psychiatric measures,
using both SCL-90R and SCID, in a slightly larger sample size and
confirmed the absence of correlation with molecular measures using
linear regression model.
In addition, we explored the effect of molecular measures on
executive functions in the premutation group but found no correlation
with either CGG repeat size, or the level of FMR1 transcript, or of
FMRP. The molecular correlates also included methylation at the FREE2
site earlier identified by Godler et al. [19] and shown to be hyper-
methylated in some PM females. Another study [14] of executive
functions and self-reported symptoms of psychiatric problems in 35
females carrying premutation proposed that methylation at the FREE2
Table 2
Comparison of clinical measures between groups.
Clinical measure Mean (SD) in control Mean (SD) in premutation Age-adjusted difference in means
(95% CI)
P-value Benjamini-Yekutieli adjusted
P-value
SCL-R90 anxiety 46.8 (9.2) 55.7 (10.7) 8.3 (2.6, 13.9) 0.005 0.049
SCL-R90 obsessive compulsive
symptoms
51.8 (8.5) 59.9 (9) 8.4 (3.4, 13.3) 0.001 0.019
SCL-R90 depression 48.7 (10.9) 58 (8.3) 9.6 (4.3, 14.9) 0.001 0.017
Working memory index 106.7 (13.4) 107.9 (12.1) 0.1 (−7.1, 7.2) 0.985 > 0.999
Working memory actual index score 110.7 (12) 107.2 (10.7) −4 (−10.4, 2.5) 0.226 > 0.999
Response control quotient 90.3 (23.5) 99.8 (15.6) 6.2 (−4.2, 16.6) 0.236 > 0.999
Attention quotient 91.9 (28) 96 (18.1) 1.2 (−11.3, 13.6) 0.851 > 0.999
Clinical measure Summary of control
scores
Summary of premutation scores Age-adjusted odds ratio (95% CI) P-value Benjamini-Yekutieli adjusted
P-value
SCID lifetime depression 1: 10 (41.7%) 1: 13 (36.1%) 1.15 (0.40, 3.29) 0.790 > 0.999
2: 2 (8.3%) 2: 3 (8.3%)
3: 12 (50%) 3: 20 (55.6%)
SCID lifetime anxiety 1: 19 (79.2%) 1: 21 (58.3%) 1.71 (0.48, 6.52) 0.410 > 0.999
2: 1 (4.2%) 2: 1 (2.8%)
3: 4 (16.7%) 3: 14 (38.9%)
SCID lifetime OCD 1: 22 (91.7%) 1: 27 (75%) 3.58 (0.76, 25.97) 0.110 0.808
2: 1 (4.2%) 2: 2 (5.6%)
3: 1 (4.2%) 3: 7 (19.4%)
Fig. 2. Scatter plots show scores of executive function including (a) working memory, (b) response control, (c) attention and clinical phenotypes (d) obsessive compulsive symptoms, (e)
depression, and (f) anxiety as a function of CGG repeat length in PBMCs between premutation group (open circle) and control group (black circle).
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region, and specifically in CpG 10–12 and 6/7, could be of benefit in
classifying premutation females into two categories of higher and lower
risk for impairments in executive functions and psychiatric symptoms.
In our current study, we used an independent sample of PM females of
comparable size. However, we did not find any correlations between
this marker and either cognitive or psychiatric status after adjusting for
age and multiple testing.
There are some plausible reasons why the FREE2 clinical correlation
results may differ in our study compared to that of Cornish and
colleagues [14]. First, the neuropsychological tests vary across the
investigations; one might have higher sensitivity and specific-to-specific
domain of executive functions more than others resulting in different
outcomes. However, if a true association exists, we expect it to be
relatively robust across executive function parameters. Second, they did
not apply adjustment for multiple testing to control the family-wise
type I error rate possibly resulting in significant correlation and/or
differences that could occur by chance. Finally, outcomes might differ
with the variation in the inclusion criteria, and method of recruitment
of the subjects.
There are some limitations in our study. First, the sample size is
relatively small hence it may not be sufficiently large to detect
associations that may exist and the mean age between in the 2 groups
was significantly different (Table 1). Second, the full repeat length
distribution was not well represented. Our study had only seven carriers
with> 100 CGG repeat whereas the majority had mid-range repeats,
which could contribute to different results from [14]. Lastly, although
the examiners were blind to the genotype of the participants, the
subjects typically knew their status and this might have affected how
they responded to the testing.
In conclusion, our results showed that female carriers in this study
had no apparent executive function deficits; however psychiatric
problems including obsessive compulsive symptoms, depression, and
anxiety were relatively common. The lack of simple correlations
between FMR1 molecular measures and these clinical outcomes suggest
the need to study more complex models in larger samples that can
account for additional genetic changes and/or environmental influ-
ences.
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